Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00647764 · ClinicalTrials.gov registry record · Phase 1
Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas
A Phase 1 study, sponsored by Esanex.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT00647764 is a Phase 1 study that has completed, run by Esanex. The registered enrollment target is 32 participants.
The verdict
NCT00647764, a Phase 1 study, has completed, sponsored by Esanex.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
Hsp90 is a chemical in the body that is involved in promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.
Interventions
- DRUG SNX-5422 Mesylate Hsp90 inhibitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2008-03 |
| Est. Completion | 2010-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00647764
The ClinicalTrials.gov registry entry for NCT00647764 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Esanex, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SNX-5422 Mesylate Hsp90 inhibitor is the first listed.
NCT00647764 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00647764 about?
NCT00647764 is a clinical study titled "Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas". Hsp90 is a chemical in the body that is involved in promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.
What is the current status of trial NCT00647764?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2008-03. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00647764?
The interventions under investigation include: SNX-5422 Mesylate Hsp90 inhibitor (DRUG).
Who is sponsoring clinical trial NCT00647764?
This trial is sponsored by Esanex, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.